Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer.

Harshabad Singh Rachel B Keller Kevin S Kapner Julien Dilly Srivatsan Raghavan Chen Yuan Elizabeth F Cohen Michael Yevgeniy Tolstorukov Elizabeth Andrews Lauren K Brais Annacarolina F L Da Silva Kimberley J Perez Douglas A Rubinson Rishi Surana Marios Giannakis Kimmie Ng Thomas E Clancy Matthew B Yurgelun Benjamin L Schlechter Jeffrey W Clark Geoffrey I Shapiro Michael H Rosenthal Jason L Hornick Valentina Nardi Yvonne Y Li Hersh V Gupta Andrew D Cherniak Matthew L Meyerson James M Cleary Jonathan Andrew Nowak Brian M Wolpin Andrew J Aguirre

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.

Keyphrases

wild type
clinical trial
transcription factor
randomized controlled trial
copy number
gene expression
dna methylation